During the past decade, Onkologische Schwerpunktpraxis Lübeck conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 5 clinical trials were completed, i.e. on average, 45.5% percent of trials that started reached the finish line to date. In the past 5 years, 8 clinical trials started and 2 clinical trials were completed. i.e. 25% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Lübeck" #1 sponsor was "Hoffmann-La Roche" with 8 trials, followed by "German CLL Study Group" with 2 trials sponsored, "Celgene" with 1 trials sponsored, "Institut de Recherches Internationales Servier" with 1 trials sponsored and "Loxo Oncology, Inc." with 1 trials sponsored. Other sponsors include -3 different institutions and companies that sponsored additional 7 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Onkologische Schwerpunktpraxis Lübeck" #1 collaborator was "ADIR, a Servier Group company" with 1 trials as a collaborator, "BeiGene Switzerland GmbH" with 1 trials as a collaborator, "Cancer Trials Ireland" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Grupo Español de Leucemia Linfocítica Crónica (GELLC)" with 1 trials as a collaborator. Other collaborators include 1 different institutions and companies that were collaborators in the rest 11 trials.

According to Clinical.Site data, the most researched conditions in "Onkologische Schwerpunktpraxis Lübeck" are "Chronic Lymphocytic Leukemia" (3 trials), "Chronic Lymphoid Leukemia" (2 trials), "Advanced Follicular Lymphoma" (1 trials), "Breast Cancer" (1 trials) and "Breast Neoplasms" (1 trials). Many other conditions were trialed in "Onkologische Schwerpunktpraxis Lübeck" in a lesser frequency.

Most popular intervention types in "Onkologische Schwerpunktpraxis Lübeck" are "Drug" (13 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Bendamustine" (3 trials), "Cyclophosphamide" (3 trials), "Obinutuzumab" (3 trials), "Fludarabine" (2 trials) and "Rituximab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Onkologische Schwerpunktpraxis Lübeck" are 14 trials for "All" genders and 1 trials for "Female" genders.

Currently, there are NaN active trials in "Onkologische Schwerpunktpraxis Lübeck". undefined are not yet recruiting, 3 are recruiting, 5 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 7 completed trials in Onkologische Schwerpunktpraxis Lübeck, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Onkologische Schwerpunktpraxis Lübeck, 1 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 9 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".